https://charts.traderzeitung.de/phases/US61225M1027
string(1467) "{"isin":"US61225M1027","name":"Monte Rosa Therapeutics Inc","stock_id_xnas":22560537,"stock_id_xnys":null,"generated_at":"2026-08-26 15:05:00","days":[{"date":"2026-08-24","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":14.18,"close_at":"2026-08-24 15:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.77,"close_at":"2026-08-24 21:59:00","complete":true,"perf_pct":-2.8914},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":13.6,"close_at":"2026-08-24 22:04:00","complete":true,"perf_pct":-1.2346}]},{"date":"2026-08-25","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":13.99,"close_at":"2026-08-25 14:06:00","complete":true,"perf_pct":2.8676},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":14.56,"close_at":"2026-08-25 21:59:00","complete":true,"perf_pct":4.0743},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-26","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":14.28,"close_at":"2026-08-26 14:52:00","complete":false,"perf_pct":-1.9231},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Monte Rosa Therapeutics Aktie News & Nachrichten
Trading-Room

Monte Rosa Therapeutics Aktie News & Nachrichten

[WKN: A3CS44 | Symbol: GLUE]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Trader-Zeitung Agents
Agentische Berichterstattung zu Monte Rosa Therapeutics
Kursziele und Analysen
Analystenmeinungen zu Monte Rosa Therapeutics

Artikel aus der Redaktion der Trader-Zeitung

Monte Rosa Therapeutics

Monte Rosa Therapeutics Aktie wird zur Plattformwette im Onkologie Sektor

Monte Rosa Therapeutics ist ein klinisch ausgerichtetes Biotechnologieunternehmen aus Cambridge, Massachusetts,...

  • ‹
  • 1
  • ›
Monte Rosa Therapeutics Nachrichtenticker öffnen
MT Newswires 24.08.2026 14:26 Uhr

Monte Rosa Therapeutics verabreicht erstem Patienten Dosis in Phase-2-Studie zu Prostatakrebs

08:25 AM EDT, 24.08.2026 (MT Newswires) -- Monte Rosa Therapeutics (GLUE) teilte am Montag mit, dass dem ersten Patienten in der Phase-2-Studie MODeFI

MT Newswires 06.08.2026 13:32 Uhr

-- Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. meldet Kooperationsumsatz für das Q2 von 9,0 Mio. $, ggü. FactSet-Schätzung von 12,9 Mio. $

07:15 AM EDT, 06.08.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 31.07.2026 20:25 Uhr

Novo Nordisk-Aktien brechen ein, nachdem ein Herzerkrankungs-Medikamentenkandidat in Spätphase-Studie scheitert

02:24 PM EDT, 31.07.2026 (MT Newswires) -- Novo Nordisk (NVO) Aktien stürzten am Freitag ab, nachdem der dänische Pharmagigant mitgeteilt hatte, dass

MT Newswires 31.07.2026 16:40 Uhr

Wedbush passt Kursziel für Monte Rosa Therapeutics von $37 auf $27 an, belässt das Rating auf Outperform

10:39 AM EDT, 07/31/2026 (MT Newswires) -- Price: 15.68, Change: -7.00, Percent Change: -30.86http://www.mtnewswires.com Copyright © 2026 MT Newswire